ERBB2 and neoplasm: Puttemans et al. [2] developed an anti-HER2 single-domain antibody (2Rs15d) conjugated with various radionuclides (e.g., 111In, 225Ac, and 131I), which significantly extended median survival in two tumor models that were less responsive to trastuzumab monotherapy.